Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 7/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.50 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.50 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.50 |
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.48 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17203936 | 0.83 | FAAH (0.81) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL15649884 | 0.83 | FAAH (0.81) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL15649498 | 0.83 | FAAH (0.81) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL8512461 | 0.83 | FAAH (0.81) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL9652090 | 0.83 | FAAH (0.81) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL342410 | 0.83 | FAAH (0.81) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL3994160 | 0.83 | FAAH (0.81) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL12350003 | 0.83 | FAAH (0.81) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL12349998 | 0.83 | FAAH (0.81) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL11216778 | 0.83 | FAAH (0.81) | FAAHMEN1KMT2AMAPK1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2476691-B1 | METHOD FOR MANUFACTURING A LIPIDIC PEPTIDE COMPOUND | NISSAN CHEMICAL IND LTD (JP) | 2018-01-03 | — | — | EP | disclosed |
| US-9180201-B2 | Method for preparing lipopeptide compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-11-10 | — | — | US | disclosed |
| US-20120253012-A1 | METHOD FOR PREPARING LIPOPEPTIDE COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-10-04 | — | — | US | disclosed |
| EP-2476691-A1 | METHOD FOR MANUFACTURING A LIPIDIC PEPTIDE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2012-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120253012-A1 | METHOD FOR PREPARING LIPOPEPTIDE COMPOUND | LPXN, VIP, NGLY1 | FAAH 669/4885MEN1 587/4885KMT2A 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.